Cognivue Names Dr. Ernest Fung as Vice President of Clinical and Medical Affairs
ROCHESTER, N.Y. (November 6, 2023)—Neuroscience technology company Cognivue, Inc. has hired Ernest Fung, PsyD, ABPP, as vice president of Clinical and Medical Affairs. A distinguished clinical and forensic neuropsychologist, he brings a wealth of experience to Cognivue’s executive leadership team.
Cognivue President and CEO Tom O’Neill said, “Dr. Fung’s rare blend of business and clinical experience, combined with his specialization in cognitive performance assessment and knowledge of neurodegenerative disorders as well as traumatic brain injury, will further advance Cognivue’s innovative work. We are privileged to welcome him to our veteran team.”
In his new role, Dr. Fung will lead the company’s efforts for foundational and clinical research, health care professional collaboration, and ongoing partnerships with the medical community.
“Cognivue’s FDA-cleared technology brings new, exciting opportunities for assessing cognition,” said Dr. Fung. “I’m thrilled to take on this position, furthering the significant research and in-market work that Cognivue has undertaken over the past several years across multiple specialties and points of access. I look forward to working with our dedicated teams to improve the science and experience of cognitive assessment for individuals, families, as well as pharmaceutical sponsors.”
Dr. Fung is a board-certified clinical neuropsychologist and a diplomate of the American Board of Clinical Neuropsychology. With a career spanning over a decade, he has collaborated with physicians from multiple disciplines to assess and treat individuals with central nervous system (CNS) disorders. Dr. Fung has also served as a clinical trial scientist, assisting biotechnology and pharmaceutical companies to maximize the quality of cognitive test data in drug development.
Furthermore, he is an expert on digital and traditional cognitive assessment techniques and approaches in neurodegenerative disorders, such as Alzheimer’s disease and other CNS conditions. He stands among the select few neuropsychologists in the United States with scientific expertise in testing instruments, rater training, and central performance and data monitoring in cognitive and functional assessment within the preclinical Alzheimer’s disease population.
Dr. Fung earned his bachelor’s degree in psychology from University College London and his doctorate in clinical psychology from the California School of Professional Psychology. In addition to his professional endeavors, Dr. Fung is a dedicated mentor and advocate for education and accreditation in clinical neuropsychology. He serves as a work sample reviewer for the American Board of Clinical Neuropsychology and an ad hoc reviewer for the Archives of Clinical Neuropsychology.
About Cognivue, Inc.
Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify, and act early on cognitive health concerns. For more information, call (585) 203-1969 or visit cognivue.com.
McDougall Communications for Cognivue, Inc.
firstname.lastname@example.org or +1.315.427.6394